Genflow Biosciences Plc has announced that Gad Berdugo, its Independent Non-Executive Chairman, will attend the BIO International Convention in San Diego, California, 22-25 June 2026, and will take part in a panel on RNA therapeutics.
Genflow describes itself as an emerging leader in longevity research. The announcement reiterates that the company focuses on gene therapies for age-related diseases and highlights its lead candidate, GF-1002, which the company claims delivers a centenarian variant of the SIRT6 gene and has produced promising preclinical results.
The company began a proof-of-concept clinical trial of the SIRT6-centenarian gene therapy in aged dogs in March 2025. Genflow also identifies a planned clinical trial of GF-1002 for metabolic dysfunction-associated steatohepatitis.
The company is listed on the London Stock Exchange and on OTCQB under the tickers GENF and GENFF.
